Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 269-275

  Kelly, Michael J ^a,b   Horan, John T ^c   Alonzo, Todd A ^d   Eapen, Mary ^e   Gerbing, Robert B ^f   He, Wensheng ^e   Lange, Beverly J ^g   Parsons, Susan K ^a,b   Woods, William G ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapy; Hematopoietic cell transplantation; Pediatrics

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; SURVIVAL RATE;

EID: 84890874028     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24739     Document Type: Article

References (35)

1. Niewerth D, Creutzig U, Bierings MB, et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116:2205-2214.
2. Chen AR, Alonzo TA, Woods WG, et al. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An American view. Br J Haematol 2002; 118:378-384.
3. Creutzig U, Reinhardt D. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A European view. Br J Haematol 2002; 118:365-377.
4. Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 2007; 13:1.
5. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. J Clin Oncol 2008; 26:5797-5801.
6. Baker KS, Bresters D, Sande JE. The burden of cure: Long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. Pediatr Clin North Am 2010; 57:323.
7. Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. Br J Haematol 2011; 155:366-376.
8. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27:4007-4013.
9. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011; 29:310-315.
10. National Cancer Institute. Bortezomib and sorafenib in patients with newly diagnosed acute myeloid leukemia with or without mutations. http://www.clinicaltrials.gov/ct2/show/NCT01371981. Published June 12, 2011. Accessed March 18, 2013.
11. Becton D, Dahl GV, Ravindranath Y, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 2006; 107:1315-1324.
12. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111:1044-1053.
13. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer 2011; 118:761-769.
14. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87:4979-4989.
15. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14:748-758.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998; 92:2322-2333.
17. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010; 28:2674-2681.
18. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28:2682-2689.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J R Stat Soc 1958; 53:457-481.
20. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 187-220.
21. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley and Sons 1980.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J R Stat Soc 1999; 94:496-509.
23. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13:1091-1112.
24. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: An international retrospective study. Blood 2007; 109:4641-4647.
25. Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: Results from the AML-BFM 98 study. Haematologica 2012; 97:21-29.
26. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: Results of the AML02 multicenter trial. Lancet Oncol 2010; 11:543.
27. Children's Oncology Group. Combination chemotherapy with or without gemtuzumab in treating young patients with newly diagnosed acute myeloid leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00372593. Published September 6, 2006. Accessed March 27, 2013.
28. Dahllöf G, Hingorani SR, Sanders JE. Late effects following hematopoietic cell transplantation for children. Biol Blood Marrow Transplant 2008; 14:88-893.
29. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29:2230-2239.
30. Ashfaq K, Yahaya I, Hyde C, et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: A systematic review. Health Technology Assessment 2010; 14:1-167.
31. Weisdorf D, Zhang MJ, Arora M, et al. Graft vs. host disease induced graft vs. leukemia effect: Greater impact on relapse and disease-free survival following reduced intensity conditioning. Biol Blood Marrow Transplant 2012; 18:1727-1733.
32. Horan JT, Logan BR, Agovi-Johnson MA, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: How much progress has been made? J Clin Oncol 2011; 29:805-813.
33. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-2101.
34. Creutzig U, van den Heuvel-Eibrink M, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012; 120:3187-3205.
35. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. Blood 2009; 114:2489-2496.